<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00141947</url>
  </required_header>
  <id_info>
    <org_study_id>BMHC-3775</org_study_id>
    <nct_id>NCT00141947</nct_id>
  </id_info>
  <brief_title>Bexarotene Treatment in Schizophrenia</brief_title>
  <official_title>Safety and Efficacy of Add-On Oral Bexarotene to Antipsychotic Treatment in Schizophrenia Patients: An Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beersheva Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stanley Medical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beersheva Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this proposed study, we aim to investigate the effects of Bexarotene (Targretin; LGD1069;
      4-[1-{5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl} ethenyl] benzoic acid) on
      severity of psychopathology, cognitive impairment, and quality of life in schizophrenia
      patients in an open label trial. The rationale behind add-on oral bexarotene to ongoing
      antipsychotic treatment in schizophrenia patients is based on both the retinoid dysregulation
      hypothesis (Goodman, 1995) and the growth factors deficiency and synaptic destabilization
      hypothesis (Moises et al, 2002) of schizophrenia. In this clinical trial, a novel regimen of
      low dose bexarotene (Targretin, 75 mg/day) will be added for 6 weeks to the standard
      treatment of 15 schizophrenia patients on stable antipsychotic treatment. Participants will
      be assessed at baseline and after 2, 4 and 6 weeks of treatment. A battery of research
      instruments will be used for assessment of efficacy and safety (psychopathology, and side
      effects). In addition, cholesterol and triglyceride levels, liver and thyroid function tests
      and a blood cell count will be monitored at baseline and during therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date>September 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Schedule for Assessment of Mental Disorder</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>The Positive and Negative Syndrome Scale</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Montgomery and Ã„sberg Depression Rating Scale</measure>
  </primary_outcome>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bexarotene (Targretin)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18-60

          -  schizophrenia

          -  stable blood parameters

          -  normal baseline fasting triglyceride

          -  ability to sign informed consent

        Exclusion Criteria:

          -  lipid abnormalities

          -  leukopenia or neutropenia

          -  organic brain damage (mental retardation)

          -  alcohol or drug abuse

          -  renal disease

          -  hepatic dysfunction

          -  history of pancreatitis

          -  thyroid axis alterations

          -  suicide attempt in past year

          -  cataracts

          -  systemic treatment with more than 15,000IU vitamin A daily

          -  patients with known hypersensitivity to bexarotene or other components of the product

          -  pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Lerner, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ben-Gurion University of the Negev</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Ritsner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Technion-Israel Institute of Technology (Haifa)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Lerner, MD, PhD</last_name>
    <phone>972-8-6401408</phone>
    <email>lernervld@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chanoch Midownik, MD</last_name>
    <phone>972-8-6401404</phone>
    <email>chanoch_m@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beersheva Mental Health Center</name>
      <address>
        <city>Beersheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vladimir Lerner, MD, PhD</last_name>
      <phone>972-8-6401408</phone>
      <email>lernervld@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Vladimir Lerner, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaar Manashe Mental Health Center</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ritsner, MD</last_name>
      <phone>9728-627-8750</phone>
      <email>ritsner@shaar-menashe.org.il</email>
    </contact>
    <investigator>
      <last_name>Michael Ritsner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2005</study_first_submitted>
  <study_first_submitted_qc>September 1, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2005</study_first_posted>
  <last_update_submitted>July 23, 2013</last_update_submitted>
  <last_update_submitted_qc>July 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beersheva Mental Health Center</investigator_affiliation>
    <investigator_full_name>Vladimir Lerner</investigator_full_name>
    <investigator_title>Associated Professor</investigator_title>
  </responsible_party>
  <keyword>bexarotene</keyword>
  <keyword>schizophrenia</keyword>
  <keyword>psychopathology</keyword>
  <keyword>cognitive impairment</keyword>
  <keyword>quality of life</keyword>
  <keyword>open lable trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bexarotene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

